Please click here to download the scientific program of the Panhellenic HELIOST Meeting, which will take place on 9-11 September 2022 at Amalia Hotel, Nafplio, Greece.
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
An FDA advisory panel on Wednesday voted 18-1 that the benefits of Amgen and UCB's monthly injection Evenity (romosozumab) outweigh its risks for the treatment of osteoporosis in postmenopausal women at high risk for fracture.